Economic Impact of Luja™ Catheter Utilizing Micro-hole Zone Technology in MS Patients

Adoption of the Luja™ catheter in MS patients reportedly reduced expenditures from € 1,039.2 million to € 1,033.1 million, leading to the prevention of 18,139 urinary tract infections (UTIs). Overall, the model suggests around 47,000 avoided UTIs and savings of € 15.8 million.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42851699)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This study highlights potential economic benefits from using the Luja™ catheter in MS patients, emphasizing cost savings and reduced UTIs, which are important for patient quality of life and healthcare budgets.

What this does not prove

The findings are based on indirect estimates and require confirmation through comparative real-world evidence, as they lack direct evaluation of the catheter's effectiveness.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 105200 · basis not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-10-07
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidence[Not Available]. ↗DOI: 10.33393/grhta.2026.3943

Supporting passages (7)

subjectseligible population included 64,600 users with SCI and 40,600 with MS.

sample sizeThe eligible population included 64,600 users with SCI and 40,600 with MS.

interventionMicro-hole Zone Technology (MhZT), implemented in the Luja™ catheter, is designed to support bladder emptying.

findingsIn patients with MS, expenditure decreased from € 1,039.2 million to € 1,033.1 million, preventing 18,139 UTIs.

findingsOverall, the model estimated approximately 47,000 avoided UTIs and € 15.8 million in related savings.

limitationsResults are mainly driven by an indirectly estimated reduction in UTIs and should be confirmed using comparative real-world evidence.

publication datePublication date: 2026-10-07

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.